Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after the bell. Here’s what to look for.

Myriad Genetics missed analysts’ revenue expectations by 0.6% last quarter, reporting revenues of $210.6 million, up 7.1% year on year. It was a mixed quarter for the company, with an impressive beat of analysts’ full-year EPS guidance estimates but full-year revenue guidance missing analysts’ expectations.

Is Myriad Genetics a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Myriad Genetics’s revenue to be flat year on year at $200.4 million, slowing from the 11.6% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.05 per share.Myriad Genetics Total Revenue

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Myriad Genetics has missed Wall Street’s revenue estimates twice over the last two years.

Looking at Myriad Genetics’s peers in the therapeutics segment, some have already reported their Q1 results, giving us a hint as to what we can expect. BioMarin Pharmaceutical delivered year-on-year revenue growth of 14.8%, beating analysts’ expectations by 1%, and United Therapeutics reported revenues up 17.2%, topping estimates by 5.6%. BioMarin Pharmaceutical traded down 1.3% following the results while United Therapeutics was also down 2.1%.

Read our full analysis of BioMarin Pharmaceutical’s results here and United Therapeutics’s results here.

There has been positive sentiment among investors in the therapeutics segment, with share prices up 4.9% on average over the last month. Myriad Genetics is down 6.3% during the same time and is heading into earnings with an average analyst price target of $15.30 (compared to the current share price of $7.56).

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.

View Comments